✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals
Market Cap
₹780 Cr.
P/E
33.79

Key Ratios

Market cap
Market cap
780 Cr
PE
PE
33.79
Prom Holding
Prom Holding
72.80 %
ROE (%)
ROE (%)
23.02
ROCE (%)
ROCE (%)
25.46
Div Yield (%)
Div Yield (%)
-
Sales
Sales
108 Cr
OPM (%)
OPM (%)
36.11 %
Debt to Equity
Debt to Equity
0.30
About
Shree Ganesh Remedies is engaged in manufacturing and dispatch of drug intermediates and chemi… Read more
Low
600
52W Range
High
950
  • Shree Ganesh Remed.
  • NGL Fine-Chem
  • Acutaas Chemicals

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

10 Yes

Positive for this company

2 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Location Wise Break-Up

Segment Wise Break-Up

Operational Metrics

    Select a Metric
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Corporate Actions
    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less
    FAQs on Shree Ganesh Remedies Ltd. Business

    Shree Ganesh Remedies produces and supplies drug intermediates and specialty chemicals for the pharmaceutical industry. Their product range includes items related to antipsychotic, antiseptic, deprotonation reactions, hyperlipidemia, alzheimers, and anti-viral drugs.

    Shree Ganesh Remed. major competitors are NGL Fine-Chem, Acutaas Chemicals, Kopran, Nectar Lifesciences, Everest Organics, SMS Lifesciences, Themis Medicare.
    Market Cap of Shree Ganesh Remed. is ₹780 Crs.
    While the median market cap of its peers are ₹629 Crs.

    Shree Ganesh Remed. seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing
    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release May Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation May Jun Sep Dec Mar Mar
    Conference Call Mar Sep
    Conference Call SummaryCon Call Summary
    Discussions & Analysis
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material